Reported 1 day ago
H.C. Wainwright analyst Joseph Pantginis has reiterated a Buy rating for Lexicon Pharmaceuticals (LXRX) with a target price of $4.00, citing the promising clinical outcomes of sotagliflozin for Type 1 Diabetes. The drug showed a significant reduction in hypoglycemic events in Phase 3 clinical trials, enhancing its appeal for T1D management. Despite acknowledging LXRX's investment potential, the analyst suggests some AI stocks may present greater upside.
Source: YAHOO